13F Holdings
中文EN

IPSC Century Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1850119 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY1,556.5%
TTM net income YoY92.4%
TTM EPS YoY91.3%
Revenue 3-yr CAGR175.9%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-15.8%
Net margin-8.8%
FCF margin-95.9%
EBITDA margin-3.8%

Returns

ROE-6.0%
ROA-3.3%
ROIC (approx.)-13.8%
Asset turnover0.38x

Leverage & solvency

Liabilities / assets29.0%
Debt / equity0.00x
Current ratio5.97x
Interest coverage—

Cash quality & payout

Operating cash flow / net income10.85x
Accruals ratio32.7%
Payout ratio—
Capex / revenue0.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$109.16M$6.59M$2.23M$5.20M—
R&D expense$95.67M$107.24M$92.71M$97.17M$75.65M
SG&A expense$24.00M$33.16M$34.71M$31.86M$19.23M
Operating income-$17.27M-$138.14M-$146.55M-$133.83M-$94.88M
Interest expense——$540,000$1.02M$1.27M
Pretax income-$9.65M-$124.78M-$134.79M-$130.84M-$95.78M
Income tax-$68,000$1.79M$1.88M$91,000$43,000
Net income-$9.58M-$126.57M-$136.67M-$130.93M-$95.82M
EBITDA-$4.17M-$124.83M-$133.50M-$125.39M-$91.14M
EPS (basic)-0.14-1.61-2.30-2.27-2.96
EPS (diluted)-0.14-1.61-2.30-2.96-2.96
Weighted avg. shares (diluted)86.56M78.65M59.31M32.39M32.39M
Balance sheet
Cash & equivalents$61.85M$61.21M$49.30M$86.24M$58.16M
Short-term investments$55.26M$130.85M$125.41M$231.23M$166.43M
Current assets$120.77M$194.05M$176.99M$319.72M$228.15M
PP&E, net$50.03M$62.14M$71.70M$82.78M$57.97M
Intangibles$34.20M$34.20M———
Total assets$223.70M$353.22M$360.69M$486.54M$437.38M
Current liabilities$20.23M$129.78M$17.85M$29.82M$15.65M
Short-term debt———$6.50M$1.04M
Long-term debt———$3.74M$8.90M
Total debt———$10.24M$9.94M
Total liabilities$64.77M$191.85M$175.94M$183.81M$41.14M
Shareholders' equity$158.94M$161.36M$184.75M$302.74M$396.24M
Net debt———-$76.00M-$48.22M
Shares outstanding87.52M85.84M60.34M55.01M58.47M
Cash flow statement
Operating cash flow-$103.88M-$110.14M-$88.35M$14.05M-$89.00M
Capital expenditure$848,000$154,000$13.74M$30.60M$44.97M
Free cash flow-$104.72M-$110.29M-$102.08M-$16.55M-$133.97M
Investing cash flow$107.50M$47.48M$61.13M-$13.13M-$298.34M
Financing cash flow$173,000$74.56M-$9.72M$27.16M$417.77M
Depreciation & amortization$13.10M$13.30M$13.04M$8.44M$3.75M
Stock-based compensation$6.84M$12.69M$14.62M$10.67M$4.66M

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.